The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INCY | +46.49% | +17.72% | +3.32% | +5,236% |
| S&P | +14.43% | +77.25% | +12.13% | +1,417% |
Incyte isn't the only drugmaker with a JAK inhibitor, but Jakafi's differentiation as a JAK1 and JAK2 inhibitor has helped the company stay on top of the treatment paradigm for myelofibrosis.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.51B | 27.8% |
| Gross Profit | $1.37B | 27.6% |
| Gross Margin | 90.88% | -0.2% |
| Market Cap | $19.39B | 45.7% |
| Market Cap / Employee | $6.82M | 0.0% |
| Employees | 2.8K | 8.7% |
| Net Income | $299.28M | 48.7% |
| EBITDA | $407.86M | 27.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.10B | 83.5% |
| Accounts Receivable | $1.02B | 20.1% |
| Inventory | 101.1 | 71.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.71M | -11.2% |
| Short Term Debt | $10.21M | 2.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 20.66% | 20.1% |
| Return On Invested Capital | 6.76% | -3.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $521.42M | 43.3% |
| Operating Free Cash Flow | $543.30M | 42.5% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 187.35 | 15.48 | 14.23 | 15.42 | -93.94% |
| Price to Book | 3.40 | 3.60 | 3.95 | 4.16 | -0.82% |
| Price to Sales | 2.72 | 2.95 | 3.55 | 3.93 | 22.35% |
| Price to Tangible Book Value | 3.69 | 3.88 | 4.23 | 4.43 | -3.74% |
| Price to Free Cash Flow TTM | 39.64 | 14.13 | 14.27 | 14.93 | -72.73% |
| Enterprise Value to EBITDA | 40.30 | 33.42 | 31.17 | 40.94 | 13.62% |
| Free Cash Flow Yield | 2.5% | 7.1% | 7.0% | 6.7% | 266.69% |
| Return on Equity | 0.5% | 24.3% | 30.4% | 29.9% | 3855.20% |
| Total Debt | $43.12M | $42.41M | $41.27M | $54.92M | -8.98% |
A number of companies suffered setbacks this year.
Checkpoint inhibitors remain top sellers, but it wasn’t all rosy news this year.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
